Edition:
United Kingdom

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

73.33USD
19 Sep 2018
Change (% chg)

$0.34 (+0.47%)
Prev Close
$72.99
Open
$72.91
Day's High
$73.66
Day's Low
$72.68
Volume
221,951
Avg. Vol
317,236
52-wk High
$95.82
52-wk Low
$67.55

Latest Key Developments (Source: Significant Developments)

Perrigo Announces Final FDA Approval And Planned Launch For The Store Brand Otc Equivalent Of Imodium Multi-Symptom Relief
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Perrigo Company PLC ::PERRIGO ANNOUNCES FINAL FDA APPROVAL AND PLANNED LAUNCH FOR THE STORE BRAND OTC EQUIVALENT OF IMODIUM MULTI-SYMPTOM RELIEF.PERRIGO COMPANY - FINALIZING PLANS TO LAUNCH WHOLLY OWNED STORE BRAND LOPERAMIDE HYDROCHLORIDE & SIMETHICONE TABLETS, 2 MG/125 MG, IN Q4 OF 2018.  Full Article

Perrigo Expands Otc Growth Strategy With Rx-To-Otc Switch Licensing For Nasonex®
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Perrigo Company Plc ::PERRIGO EXPANDS OTC GROWTH STRATEGY WITH RX-TO-OTC SWITCH LICENSING FOR NASONEX®.FINANCIAL TERMS OF THE LICENSING AGREEMENT WERE NOT DISCLOSED.UNDER TERMS OF AGREEMENT, CO HOLDS RIGHTS TO MARKET, SELL, DISTRIBUTE A NON-PRESCRIPTION VERSION OF NASONEX(®) OTC IN THE UNITED STATES .AGREEMENT WITH SUBSIDIARY OF MERCK FOR EXCLUSIVE RIGHTS IN UNITED STATES TO PURSUE REGULATORY APPROVAL FOR NON-PRESCRIPTION, OTC NASONEX NASAL SPRAY.  Full Article

Perrigo Announces Plan To Separate Prescription Pharmaceuticals Business
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Perrigo Company PLC ::PERRIGO ANNOUNCES PLAN TO SEPARATE PRESCRIPTION PHARMACEUTICALS BUSINESS.BOARD WILL CONSIDER ALL VALUE-ENHANCING OPTIONS, INCLUDING A POSSIBLE TAX-EFFICIENT SEPARATION TO SHAREHOLDERS, A SALE OR MERGER.BOARD APPROVED PLAN TO SEPARATE COMPANY'S PRESCRIPTION PHARMACEUTICALS BUSINESS FOLLOWING PREVIOUSLY ANNOUNCED STRATEGIC PORTFOLIO REVIEW.SEPARATION IS CURRENTLY EXPECTED TO BE COMPLETED DURING SECOND HALF OF 2019.HAS ENGAGED BARCLAYS AS ITS FINANCIAL ADVISOR TO LEAD SEPARATION PROCESS.  Full Article

Perrigo Reports Q2 Adjusted Earnings Per Share $1.22
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Perrigo Company PLC ::REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 GAAP EARNINGS PER SHARE $0.26.Q2 EARNINGS PER SHARE VIEW $1.28 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $4.75 TO $4.95.SEES FY 2018 EARNINGS PER SHARE $2.11 TO $2.31.Q2 SALES $1.2 BILLION VERSUS I/B/E/S VIEW $1.25 BILLION.Q2 ADJUSTED EARNINGS PER SHARE $1.22 EXCLUDING ITEMS.EXPECTS CALENDAR YEAR 2018 NET SALES TO BE IN THE RANGE OF $4.8 BILLION TO $4.9 BILLION.PERRIGO COMPANY - EXPECTS 2018 ADJUSTED OPERATING INCOME IN RANGE OF $960 MILLION TO $990 MILLION, AN ADJUSTED EFFECTIVE TAX RATE OF ABOUT 20.0%.  Full Article

Hikma Enters Licensing Partnership With Perrigo
Monday, 9 Jul 2018 

July 9 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA ENTERS LICENSING PARTNERSHIP WITH PERRIGO.SIGNED LICENSING AND DISTRIBUTION AGREEMENT WITH OMEGA PHARMA TRADING NV.HIKMA HAS EXCLUSIVE RIGHT TO LICENSE AND DISTRIBUTE MORE THAN 30 CONSUMER HEALTHCARE PRODUCTS IN ALL ITS MENA MARKETS.IN ADDITION, HIKMA HAS RIGHT OF FIRST REFUSAL TO FULL RANGE OF PERRIGO'S OTC MEDICINES IN MENA REGION.  Full Article

Perrigo Confirms Patent Challenge For Generic Version Of Sernivo Spray, 0.05%
Thursday, 24 May 2018 

May 24 (Reuters) - Perrigo Company PLC ::PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF SERNIVO SPRAY, 0.05%.PERRIGO COMPANY - PROMIUS PHARMA LLC INITIATED PATENT LITIGATION ON MAY 22, 2018 IN COURT.PERRIGO COMPANY - PATENT LITIGATION REGARDING PERRIGO'S PARAGRAPH IV ABBREVIATED NEW DRUG APPLICATION FOR BETAMETHASONE DIPROPIONATE, 0.05% SPRAY.  Full Article

Perrigo Confirms First To File Patent Challenge For Generic Ultravate Lotion
Monday, 14 May 2018 

May 14 (Reuters) - Perrigo Company PLC ::PERRIGO CONFIRMS FIRST TO FILE PATENT CHALLENGE FOR GENERIC VERSION OF ULTRAVATE LOTION, 0.05%.PERRIGO COMPANY PLC - SUN PHARMACEUTICAL INDUSTRIES & MICAL PHARMACEUTICALS INITIATED PATENT LITIGATIONS ON MAY 9 & 10, 2018.PERRIGO COMPANY PLC - LITIGATIONS REGARDING PARAGRAPH IV ABBREVIATED NDA FOR HALOBETASOL PROPIONATE LOTION, 0.05%.  Full Article

Perrigo Company Reports Q1 Adjusted EPS Of $1.26 Excluding Items
Tuesday, 8 May 2018 

May 8 (Reuters) - Perrigo Company PLC ::REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 GAAP EARNINGS PER SHARE $0.57.Q1 EARNINGS PER SHARE VIEW $1.16 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $5.05 TO $5.45.SEES FY 2018 EARNINGS PER SHARE $2.90 TO $3.30.Q1 ADJUSTED EARNINGS PER SHARE $1.26 EXCLUDING ITEMS.Q1 SALES $1.2 BILLION VERSUS I/B/E/S VIEW $1.21 BILLION.SEES FY 2018 SALES $5.0 BILLION TO $5.1 BILLION.FY2018 EARNINGS PER SHARE VIEW $5.26, REVENUE VIEW $5.06 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Perrigo Launches Novel Omeprazole Orally Disintegrating Tablet to Treat Frequent Heartburn
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Perrigo Company PLC ::SAYS LAUNCH OF STORE BRAND OMEPRAZOLE DELAYED RELEASE ORALLY DISINTEGRATING TABLETS 20MG.  Full Article

Perrigo Says Terminated Existing Credit Agreements
Friday, 9 Mar 2018 

March 9 (Reuters) - Perrigo Company Plc ::PERRIGO - EFFECTIVE MARCH 8, CO TERMINATED EXISTING CREDIT AGREEMENTS & REPLACED THEM WITH A NEW SENIOR UNSECURED REVOLVING AND TERM LOAN CREDIT AGREEMENT.PERRIGO SAYS ‍NEW CREDIT AGREEMENTS PROVIDE FOR $1.0 BILLION SENIOR UNSECURED REVOLVING LINE OF CREDIT, EUR350 MILLION IN SENIOR UNSECURED TERM LOAN FINANCING​.  Full Article

Photo

Perrigo plans to separate prescription pharma business

Perrigo Co Plc said on Thursday it would separate its generics prescription business, which has been a drag on results, to focus on consumer healthcare following a strategic review, sending the drugmaker's shares down about 8 percent.